^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH antagonist

    Related drugs:
    5d
    Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, Sean Sachdev | Trial primary completion date: Nov 2028 --> Nov 2030
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    enzalutamide • Orgovyx (relugolix)
    5d
    Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (clinicaltrials.gov)
    P3, N=97, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting | N=297 --> 97 | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Mar 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    13d
    Debio 4228-201: A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Debiopharm International SA | Trial primary completion date: Dec 2026 --> Jun 2026 | Trial completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    28d
    SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov)
    P3, N=1164, Completed, Sumitomo Pharma Switzerland GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    Orgovyx (relugolix)
    1m
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Recruiting, Jose Pablo Leone | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    1m
    The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University Hospital, Geneva | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    2ms
    Triplet therapy combined with robot-assisted cytoreductive prostatectomy in high-volume metastatic prostate cancer: a prospective, multicentre, randomized controlled trial (ChiCTR2600121819)
    P=N/A, N=88, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    docetaxel • Firmagon (degarelix)
    2ms
    Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Orgovyx (relugolix)
    2ms
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • enzalutamide • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2ms
    OPTYX: A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (clinicaltrials.gov)
    P=N/A, N=999, Active, not recruiting, Sumitomo Pharma America, Inc. | Trial completion date: May 2028 --> Jul 2026 | Trial primary completion date: May 2028 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Orgovyx (relugolix)
    2ms
    Role of Menopause in Thermoregulation (clinicaltrials.gov)
    P4, N=24, Recruiting, Penn State University | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    2ms
    TASUC-Neo: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (clinicaltrials.gov)
    P1, N=2, Terminated, Brown University | N=32 --> 2 | Trial completion date: Jan 2032 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Jul 2025; Principal Investigator left institution
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    AR positive
    |
    cisplatin • gemcitabine • Firmagon (degarelix)